BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38720801)

  • 1. Drug-eluting beads transcatheter arterial chemoembolization combined with systemic therapy versus systemic therapy alone as first-line treatment for unresectable colorectal liver metastases.
    Wang F; Chen L; Bin C; Cao Y; Wang J; Zhou G; Zheng C
    Front Oncol; 2024; 14():1338293. PubMed ID: 38720801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of transarterial chemoembolization with drug-eluting beads combined with systemic chemotherapy and targeted therapy in colorectal cancer liver metastasis.
    Chen YC; Huang CW; Li CC; Chang TK; Su WC; Chen PJ; Yeh YS; Chang YT; Tsai HL; Shih MP; Wang JY
    World J Surg Oncol; 2023 Dec; 21(1):378. PubMed ID: 38041083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens.
    Cao F; Zheng J; Luo J; Zhang Z; Shao G
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):2993-3002. PubMed ID: 34302208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting bead transarterial chemoembolization (DEB-TACE) versus conventional transarterial chemoembolization (cTACE) in colorectal liver metastasis: Efficacy, safety, and prognostic factors.
    Zhang H; Wu C; Chen M; Sun Y; Han J
    J Cancer Res Ther; 2023 Dec; 19(6):1525-1532. PubMed ID: 38156918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma.
    Huang J; Huang W; Zhan M; Guo Y; Liang L; Cai M; Lin L; He M; Lian H; Lu L; Zhu K
    J Hepatocell Carcinoma; 2021; 8():1445-1458. PubMed ID: 34858889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma.
    Bi Y; Shi X; Ren J; Yi M; Han X; Song M
    BMC Gastroenterol; 2021 May; 21(1):231. PubMed ID: 34020608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipiodol combined with drug-eluting beads versus drug-eluting beads alone for transarterial chemoembolization of hepatocellular carcinoma: a multicenter study.
    Ji K; Shi Y; Liang Z; Zhang C; Jing L; Xu T; Cao S; Zhou G; Cao Y; Niu J; Zhu J; Ai J; Li Z; Chen F
    Acad Radiol; 2024 Jun; ():. PubMed ID: 38866689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
    Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
    World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of raltitrexed-eluting CalliSpheres
    Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
    Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer.
    Bi Y; Li F; Ren J; Han X
    Front Pharmacol; 2022; 13():1079707. PubMed ID: 36518678
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of CalliSpheres® microspheres versus conventional transarterial chemoembolization in the treatment of refractory colorectal cancer liver metastasis.
    Li H; Zhang X; Zhao W; Cai F; Qin J; Tian J
    BMC Cancer; 2023 Oct; 23(1):970. PubMed ID: 37828491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
    Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients.
    Li N; Chen J
    Ir J Med Sci; 2022 Dec; 191(6):2611-2617. PubMed ID: 35083645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial experience of drug-eluting bead transarterial chemoembolization with CalliSpheres
    Zhang G; Tang R; Wu J; Jin K; Chao M; Li B
    Transl Cancer Res; 2020 Mar; 9(3):1630-1639. PubMed ID: 35117511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis.
    Bi Y; Jiao D; Wang Y; Han X; Ren J
    World J Surg Oncol; 2022 Jul; 20(1):229. PubMed ID: 35821043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases.
    Sljivic M; Sever M; Ocvirk J; Mesti T; Brecelj E; Popovic P
    Radiol Oncol; 2024 Jun; 58(2):214-220. PubMed ID: 38553252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 19. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.
    Do Minh D; Chapiro J; Gorodetski B; Huang Q; Liu C; Smolka S; Savic LJ; Wainstejn D; Lin M; Schlachter T; Gebauer B; Geschwind JF
    Eur Radiol; 2017 Dec; 27(12):4995-5005. PubMed ID: 28677067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative transarterial chemoembolization with drug-eluting beads (DEB-TACE) in patients undergoing conversional hepatectomy: a propensity-score matching analysis.
    Liu Y; Zhou B; Tang W; Xu D; Yan Z; Ren L; Zhu D; He G; Wei Y; Chang W; Xu J
    Eur Radiol; 2023 Feb; 33(2):1022-1030. PubMed ID: 36066736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.